Background Breast cancer is the first female cancer, especially after menopause. In Morocco its prevalence estimated at 35.8%. Its hormone-dependent aspect requires use of hormone-modulating treatments, in particular aromatase-inhibitors responsible for hypogonadism, bone loss and osteoporosis (OP) with increased fracture risk. Objectives The aim this study to determine epidemiological, clinica...
